ATHIX
Price
$26.14
Change
+$0.50 (+1.95%)
Updated
Jun 15 closing price
Net Assets
5.46B
JDMAX
Price
$143.11
Change
+$1.49 (+1.05%)
Updated
Jun 15 closing price
Net Assets
22.28B
Interact to see
Advertisement

ATHIX vs JDMAX

Header iconATHIX vs JDMAX Comparison
Open Charts ATHIX vs JDMAXBanner chart's image
ATHIX vs JDMAX Comparison Chart in %
View a ticker or compare two or three
VS
ATHIX vs. JDMAX commentary
Jun 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHIX is a Hold and JDMAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JDMAX has more cash in the bank: 22.3B vs. ATHIX (5.46B). ATHIX (0.00) and JDMAX (0.00) have matching dividends . ATHIX was incepted earlier than JDMAX: ATHIX (29 years) vs JDMAX (17 years). JDMAX (1.14) is less costly to investors than ATHIX (0.80). ATHIX is a more actively managed with annual turnover of: 62.00 vs. JDMAX (17.00). JDMAX has a lower initial minimum investment than ATHIX: JDMAX (2500) vs ATHIX (5000000). JDMAX annual gain was more profitable for investors over the last year : 7.08 vs. ATHIX (-11.03). JDMAX return over 5 years is better than : -13.16 vs. ATHIX (-14.10).
ATHIXJDMAXATHIX / JDMAX
Total Expense Ratio0.801.1470%
Annual Report Gross Expense Ratio0.801.1470%
Fund Existence29 years17 years-
Gain YTD3.9747.60252%
Front LoadN/A6%-
Min. Initial Investment50000002500200,000%
Min. Initial Investment IRAN/AN/A-
Net Assets5.46B22.3B24%
Annual Yield % from dividends0.000.00-
Returns for 1 year-11.037.08-156%
Returns for 3 years9.4813.1872%
Returns for 5 years-14.10-13.16107%
Returns for 10 years15.8163.4925%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCHP100.325.08
+5.33%
Microchip Technology
PSNL9.790.20
+2.09%
Personalis
REZI31.62-0.04
-0.13%
Resideo Technologies
NCEL3.20-0.03
-0.93%
NewcelX Ltd.
LENZ6.65-0.12
-1.77%
LENZ Therapeutics